Nautilus Biotechnology, Inc. NAUT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 190.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 190.00K | -- | -- | -- |
| Cost of Revenue | -- | 15.00K | -- | -- | -- |
| Gross Profit | -- | 175.00K | -- | -- | -- |
| SG&A Expenses | -- | 6.33M | 6.42M | 5.85M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 15.95M | 16.12M | 15.42M | 15.47M |
| Operating Income | -- | -15.76M | -16.12M | -15.42M | -15.47M |
| Income Before Tax | -- | -14.47M | -14.70M | -13.78M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -14.47M | -14.70M | -13.78M | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -14.47M | -14.70M | -13.78M | -13.57M |
| EBIT | -- | -15.76M | -16.12M | -15.42M | -15.47M |
| EBITDA | -- | -15.49M | -15.79M | -15.02M | -15.05M |
| EPS Basic | -0.12 | -0.11 | -0.12 | -0.11 | -0.11 |
| Normalized Basic EPS | -0.08 | -0.07 | -0.07 | -0.07 | -0.07 |
| EPS Diluted | -0.12 | -0.11 | -0.12 | -0.11 | -0.11 |
| Normalized Diluted EPS | -0.08 | -0.07 | -0.07 | -0.07 | -0.07 |
| Average Basic Shares Outstanding | 127.24M | 127.14M | 126.63M | 126.37M | 126.31M |
| Average Diluted Shares Outstanding | 127.24M | 127.14M | 126.63M | 126.37M | 126.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |